ClinicalTrials.gg
Not yet recruitingNCT07506928NEURO-PULSEUpdated Apr 2, 2026

NEURO - Prognostication Using Late Somatosensory Evoked - Potentials

An interventional study of EEGs in Comatose, Prognosis and Critical Care, sponsored by University Hospital, Bordeaux. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The main aim of this study is to develop a new technique for the passive diagnosis of cognitive-motor dissociation, with the detection of motor intention in a comatose patient by analysing the EEG signal and in particular the ERD/ERS amplitudes in the motor cortex after stimulation of the median nerve.

Read the detailed description

The utilisation of brain-computer interfaces (BCI) employing median nerve stimulation has the potential to yield novel insights into the enhancement of neuroprognostication. The application of painless, low-intensity electrical stimulation to the median nerve has been shown to activate the somatosensory cortex and the motor cortex via cutaneous and proprioceptive afferents. The activation in question has been shown to induce specific modulations of the electroencephalogram (EEG) signal, characterised by event-related desynchronisation (ERD) during stimulation, followed by resynchronisation (ERS) afterwards. The application of this stimulation during a motor task - that is to say, voluntary movement or motor imagery - results in a marked attenuation of post-stimulation ERS, or even its complete absence. The intention to move a hand, when coinciding with median nerve stimulation, amplifies the cortical ERD/ERS signatures, and is made more easily detectable by machine learning algorithms.

The main aim of this study is to develop a new technique for the passive diagnosis of cognitive-motor dissociation, with the detection of motor intention in a comatose patient by analysing the EEG signal and in particular the ERD/ERS amplitudes in the motor cortex after stimulation of the median nerve.

02

Conditions studied

  • Comatose
  • Prognosis
  • Critical Care

Browse trials for

Keywords

  • Prognostication
  • Somatosensory evoked - potentials
  • Neurocritical care
  • Machine learning
  • Continuous EEG
03

In context

Coma

138 studies on the registry are indexed under Coma; 35 are open to participants now.

This study's planned enrollment of 50 is below the median of 85 across 77 interventional studies indexed under Coma.

Browse Coma studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 806 studies on the registry; 197 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be aged 18 years or over;
  • Patients must be admitted to the intensive care unit with a cerebrovascular pathology;
  • Patients must be in a comatose state with a Glasgow score strictly less than 8, 24 hours after stopping sedation.
  • Representative of the patient informed of the research and not objecting to it, information and collection of the participant's non-objection if recovery of the ability to understand the content of the information note,
  • The patient is a recipient of or affiliated with a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Bilateral lesions of the motor cortex or cortico-spinal fasciculus,
  • Cutaneous infection of the scalp or any other lesion making surface electroencephalography impossible,
  • Patient whose short-term survival (48 - 72 hours) seems compromised,
  • Severe peripheral neuromyopathy,
  • Severe Acute Respiratory Distress Syndrome at the time of screening,
  • Hearing-impaired patients with hearing aids,
  • Pregnant or breastfeeding woman,
  • Patient under legal protection (persons deprived of their liberty or under guardianship).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Patient

    Patients admitted to the intensive care unit with a cerebrovascular pathology and in a comatose state with a Glasgow score strictly less than 8, 24 hours after stopping sedation.

    Other: EEGs

Interventions

  • OtherEEGs

    All patients included in the study will receive electroencephalograms (EEGs) of post-stimulation event-related desynchronisation (ERD)/event-related synchronisation (ERS) amplitudes of the median nerve on two occasions per week. These recordings will be made twice a day, once in the morning and once in the afternoon/evening, in order to take account of the patients' inherent nycthemeral rhythm. A recording of 12 EEG electrodes from the scalp will be made during painless stimulation of the median nerve. The intensity of this stimulation will range from 3 to 14 mA, with a duration of 0.1 ms and a frequency of 5 Hz. This will result in a multiplication of the recording periods during and after stimulation. A final period of approximately 15 minutes of recording will be carried out with headphones on the patient, using simple, pre-recorded, standardized commands. These recordings will be continued for a period of three weeks following their inclusion.

06

What researchers measure

Primary outcomes

  1. Alterations in the electroencephalogram

    The alterations in the electroencephalogram (EEG) signal in the event-related desynchronisation/event-related synchronisation cortical signature following median nerve stimulation will be analysed and correlated with the emergence of clinical motor intention. The detection of cognitive-motor dissociation will rely on classification algorithms that detect the presence of motor activity in EEG signals following median nerve stimulation (MNS). The EEG signals recorded immediately after MNS will be represented as one or more covariance matrices, and several classifiers, including Riemannian classifiers, will then be trained on these matrices to classify a state of rest or motor activity in the EEG.

    Time frame: 3 weeks after inclusion

  2. CRS-R score

    Progression of the Clinical Rating Scale-Revised (CRS-R) score: Standardized clinical scale assessing level of consciousness across six subdomains: auditory, visual, motor, oromotor/verbal, communication, and arousal. Total score: 0 to 23 Interpretation: Lower scores indicate absence or very low levels of consciousness (coma or vegetative state/unresponsive wakefulness syndrome). Intermediate scores indicate minimal but definite behavioral evidence of consciousness (minimally conscious state). Higher scores indicate more complex behaviors consistent with a higher level of consciousness (emergence from the minimally conscious state).

    Time frame: 3 weeks after inclusion

  3. Glasgow score

    Glasgow Coma Scale (GCS) Standardized clinical scale assessing level of consciousness based on three components: eye opening, verbal response, and motor response. Total score: 3 to 15 Interpretation: Lower scores indicate severe impairment of consciousness (coma or deep unconsciousness). Intermediate scores indicate moderate impairment of consciousness. Higher scores indicate mild or no impairment of consciousness.

    Time frame: 3 weeks after inclusion

Secondary outcomes

  1. GOS-E

    The functional neurological prognosis in the period subsequent to the event will be evaluated by the Glasgow Outcome Scale-Extended (GOS-E) Standardized clinical scale assessing functional outcome and disability following brain injury, based on overall level of independence and social functioning. Total score: 1 to 8 Interpretation: Lower scores indicate severe disability or death. Intermediate scores indicate moderate disability with some level of independence. Higher scores indicate good recovery with return to independent functioning.

    Time frame: 6 months after inclusion

  2. SF36

    The functional neurological prognosis in the period subsequent to the event will be evaluated by the Short Form-36 Health Survey (SF-36) Standardized patient-reported outcome measure assessing health-related quality of life across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional problems, and mental health. Score range: 0 to 100 for each domain (and summary scores) Interpretation: Lower scores indicate poorer health-related quality of life. Higher scores indicate better health-related quality of life.

    Time frame: 6 months after inclusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07506928
Collaborators
Inria, the French National Institute for computer science and applied mathematics
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 2, 2026

Study contacts

Geoffroy MOUCHEBOEUF, MD
Contact
geoffroy.moucheboeuf@chu-bordeaux.fr
05 57 82 19 95 ext. +33
Grégoire CANE, MD
Contact
gregoire.cane@chu-bordeaux.fr
Geoffroy MOUCHEBOEUF, MD
principal investigator · University Hospital, Bordeaux
Grégoire CANE, MD
study director · University Hospital, Bordeaux
Fabien LOTTE
study chair · Institut National de Recherche en Informatique et en Automatique

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion